TITLE:
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

CONDITION:
Carcinoma, Non-Small-Cell Lung

INTERVENTION:
TRAIL-R1 mAb (TRM-1;HGS-ETR1)

SUMMARY:

      The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with
      relapsed or refractory non-small cell lung cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Primary Inclusion Criteria:

          -  Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or
             recurrent NSCLC

          -  Previously treated and failed to respond to standard therapy or progressed after
             standard therapy

          -  18 years of age or older

        Primary Exclusion Criteria:

          -  Received a non-FDA approved investigational agent within the last 4 weeks.

          -  Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or
             radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized
             monoclonal antibodies

          -  Infection requiring antibiotics or hospitalization within the last 2 weeks

          -  HIV, Hepatitis-B, Hepatitis-C

          -  Pregnant or breast-feeding women

          -  Major surgery within the last 4 weeks

          -  History of other cancers within the past 5 years
      
